S. Fox

发表

Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators

Steven V. Fox, J. Uslaner, J. Renger, 2013, Front. Neurosci..

Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.

Steven V. Fox, John D. Schreier, J. Renger, 2014, Bioorganic & medicinal chemistry letters.

Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.

Steven V. Fox, I. Raheem, J. Renger, 2015, Bioorganic & medicinal chemistry letters.

Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs

Steven V. Fox, J. Uslaner, J. Renger, 2014, Front. Behav. Neurosci..

Discovery of [(2R,5R)‐5‐{[(5‐Fluoropyridin‐2‐yl)oxy]methyl}‐2‐methylpiperidin‐1‐yl][5‐methyl‐2‐(pyrimidin‐2‐yl)phenyl]methanone (MK‐6096): A Dual Orexin Receptor Antagonist with Potent Sleep‐Promoting Properties

Steven V. Fox, John D. Schreier, S. Doran, 2012, ChemMedChem.

Decreased complexity of glucose dynamics in diabetes in rhesus monkeys

Steven V. Fox, L. Gantert, S. Fox, 2019, Scientific Reports.

Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity

Steven V. Fox, J. Uslaner, Sean M. Smith, 2016, Psychopharmacology.

Discovery of a Pharmacologically Active Antagonist of the Two‐Pore‐Domain Potassium Channel K2P9.1 (TASK‐3)

Steven V. Fox, S. Doran, J. Renger, 2012, ChemMedChem.

The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold

Steven V. Fox, J. Uslaner, J. Renger, 2013, BMC Neuroscience.

Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists.

Steven V. Fox, James C Barrow, Cuyue Tang, 2010, Bioorganic & medicinal chemistry letters.

Discovery of 4,4-Disubstituted Quinazolin-2-ones as T-Type Calcium Channel Antagonists.

Steven V. Fox, S. Doran, G. McGaughey, 2010, ACS medicinal chemistry letters.

Discovery of 5′′‐Chloro‐N‐[(5,6‐dimethoxypyridin‐2‐yl)methyl]‐2,2′:5′,3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia

Steven V. Fox, John D. Schreier, J. Renger, 2014, ChemMedChem.